We describe a rapid, simple HPLC method routinelyused in our clinical laboratory for determining amiodarone and its metabolite desethylamiodarone. These compounds are released from serum proteins by pretreatment with an acidic solution and then extracted onto a C2 reversedphase clean-up column. After elution from the extraction column, the compounds are separated and quantified by HPLC with a C18 reversed-phase column and spectrophotometric detection. The standard curves for the drug and metabolite are linear up to 20.0 mg/L, with a lower limit of detection of 0.16 mg/L. The CVs for intra-assay precision were 5.0% at 0.58 mg/L and 2.9% at 5.96 mg/L; for inter-assay precision, they were 9.6% at 0.52 mg/L and 6.1% at 2.09 mg/L. Lipemia, hemoglobin, and bilirubinup to 300 mg/L do not interfere with this assay. None of >550 cardiac patients' samples tested contained a compound that interferes with this assay. The primary metabolite of amiodarone is desethylamiodarone, (2-butyl-3-benzofurany1){4-[2-(ethybmino)ethoxy}-3,5-diiodophenyl}methanone (Figure 1) , the result of N-dealkylation.
The primary metabolite of amiodarone is desethylamiodarone, (2-butyl-3-benzofurany1){4-[2-(ethybmino)ethoxy}-3,5-diiodophenyl}methanone (Figure 1 ), the result of N-dealkylation.
In all species studied, including humans, urinary excretion accounts for very little drug elimination, whereas biliary excretion and fecal elimination account for 65-75% of the drug taken (1). 
For controls as well as standards,
we also routinely use aged serum (frozen pool) from patients not taking amiodarone, as an alternative to fresh serum. Also, although amiodarone and desethylamiodarone are freely soluble in methanol and ethanol, these compounds are only slightly soluble in water, making it difficult to formulate aqueous standards.
Equipment.
Vac-Elut apparatus (Varian Sample Preparation Products, Harbor City, CA) was used for the solid-phase extractions. We used a Hewlett-Packard (Palo Alto, CA) HPLC system (Model 1090M) with a diode-array datector at 242 nm at 0.02 A full-scale. The flow rate was 1.5 mL/min, the oven temperature 40#{176}C, the injection volume 50 &L, and the run time 15 mm. Sample preparation (12) consisted of pipetting 0.5 mL of standard, control, or patient's specimen into a labeled 1.5-mL Eppendorf tube, followed by 0.3 mL of 2.0 mol/L sodium acetate, pH 4.5, and 10 L of internal standard, and vortex-mixing for 5-10 s. The C2 extraction columns were conditioned by washing the columns with 1.0 mL of methanol and then with 1.0 mL of water. The pretreated samples were applied to the extraction columns under suction. The columns were then washed sequentially with 1.0 mL of water, 1.0 mL of 500 mL/L methanol, and 1 mL of 500 mLIL acetomtrile. (We have found that the solid-phase extraction columns must not be allowed to dry on the Vac-Elut for longer than 2-3 mm after activation with water and methanol; otherwise, the recovery of analytes decreases and becomes inconsistent.) The analytes were then eluted from the columns with 0.5 mL of mobile phase.
Precision studies. Intra-assay precision was assessed at two different analyte concentrations (n = 10). Each sample was pretreated by solid-phase extraction as described above. Inter-assay precision was assessed at two different concentrations of the control material, prepared as described above, assayed over 40 days. -----..7.-...----.- The results of intra-and inter-assay precision studies are given in Table 2 . Control material prepared with lyophilized drug-free serum (e.g., Bio-Rad cat. no. C-458-10) will not work with this assay because this material contains many interfering peaks that are not present when fresh serum is used for preparing control materials.
The assay range for amiodarone and desethylamiodarone is 0.0-20.0 mgIL. The detection limit for ammodarone and desethylanuodarone is 0.16 mg/L. Below this concentration, the peaks are too small for accurate Absolute recovery is shown in Table 3 . Essentially all of the amiodarone and desethylamiodarone applied to the C2 extraction columns is recovered. A high proportion of triflupromazine is also consistently recovered.
Hemoglobin concentrations 10.0 gIL and bilirubin concentrations up 300 mgfL had little or no effect on drug measurements. Lipemia was simulated by adding Intralipid to serum in concentrations 10 gIL-equivalent to triglyceride concentrations up to 25 g/L (12)-which had no effect on the amiodarone assay. We have performed >350 assays on serum from cardiology patients taking amiodarone and have not encountered any interfering peaks with this assay. We also extracted and analyzed Bio-Rad TDM therapeutic drug monitoring controls, levels 1, 2, and 3 (cat. no. C-455 I, II, & Ill); none of the constituents in these controls (Table 4) interferes with this assay.
Discussion
We investigated zinc sulfate/acetomtrile protein pre- Ultracentrifugation binding studies (14) have shown that 96.3 ± 0.6% of ainiodarone is bound to plasma proteins. Gel-ifitration analysis of serum proteins tracelabeled with lssIlabeled amiodarone shows that this drug is chiefly carried by albumin (62.1%) with much of the remainder (33.5%) being bound to a high-Me protein, most likely 3-lipoprotein (14). Our studies show the pH dependence of the release of amiodarone from serum proteins, a pH of 4.5 being necessary for good recovery in the solid-phase extraction procedure.
The compound L8040, a brominated benzothiophene structurally very similar to amiodarone, has been used by many investigators as an internal standard for the analysis of amiodarone by HPLC (9, 10, 15) . However, this chemical is not available in the US and is no longer being manufactured. Initially, we tried trifluoperazine, a compound that migrates between amiodarone and desethylamiodarone (11), as an internal standard. The peak shape is very broad and flat in our assay and the recovery of this material is quite low. Instead, triflupromazine has proved to be a consistent and reliable internal standard.
Various possible interferenta were investigated.
Hemoglobin, lipids, and biirubin 300 mg/L do not interfere. We found that bilirubin concentrations >300 mg/L produced a large enough peak -1.5 mm before the internal standard, near the column void, to cause the internal standard to be falsely increased. This resulted in a decrease of -10-20% in the calculated amiodarone and desethylamiodarone results.
Bio-Rad TDM controls were analyzed to detect compounds that might interfere with this assay. We found that these controls contained a peak that had the same retention time and spectral characteristics as arniedarone. The package insert did not list amiodarone as one of the constituents; however, the manufacturer did confirm that amiodarone was added to these control materials as an experiment to see if amiodarone would be stable in this matrix. The amiodarone concentrations we measured were about half the target value, indicating that azniodarone may not be stable in a lyophilized matrix. Bio-Rad is working on a possible liquid control with amiodarone as one of the constituents. Propoxyphene is also present in the Bio-Rad TDM controls, but is not listed on the package insert.
The Vacutainer gel separator (SST) tube (Becton-Dickinson, Rutherford, NJ) is commonly used in hospitals to collect blood. We investigated whether these tubes could cause a change in the concentration of amiodarone and desethylamiodarone by placing drug-supplemented samples in plain tubes and SST tubes on a rocker for 2 h. We, like others (16), saw no differences between the sample tubes at analyte concentrations of 0.5 and 2.0 mg/L. We also noted that these samples were allowed to rock unprotected from the fluorescent laboratory lights. Previous publications have stated that amiodarone and desethylamiodarone are light-sensitive (1). However, we saw no changes in their concentrations with routine exposure to our clinical laboratory lighting. 
